Clinical trial
Erythropoietin (EPO) and Granulocyte-Colony Stimulating Factor (G-CSF) for…
NCT00234143 · St. Bartholomew's Hospital, Other · Unknown status
Key facts
| NCT number | NCT00234143 |
|---|---|
| Title | Erythropoietin (EPO) and Granulocyte-Colony Stimulating Factor (G-CSF) for Low-Risk Myelodysplastic Syndromes (MDS) |
| Official title | A Randomised Controlled Trial of Prolonged Treatment With Darbepoetin Alpha With or Without Recombinant Human Granulocyte Colony Stimulating Factor (G-CSF) Versus Best Supportive Care in Patients With Low-Risk Myelodysplastic Syndromes |
| Lead sponsor | St. Bartholomew's Hospital, Other |
| Status | Unknown status |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndromes |
| Intervention type | Behavioral, Drug |
| Interventions | Darbepoetin and Filgrastim, Darbepoetin |
| Enrollment | 360 |
| Start date | Oct 1, 2004 |
| First posted | Oct 6, 2005 |
| Last update posted | Mar 12, 2009 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: